Is MaxCyte Stock a Good Investment?
MaxCyte Investment Advice | MXCT |
- Examine MaxCyte's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research MaxCyte's leadership team and their track record. Good management can help MaxCyte navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact MaxCyte's business and its evolving consumer preferences.
- Compare MaxCyte's performance and market position to its competitors. Analyze how MaxCyte is positioned in terms of product offerings, innovation, and market share.
- Check if MaxCyte pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about MaxCyte's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in MaxCyte stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if MaxCyte is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine MaxCyte Stock
Researching MaxCyte's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 74.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.68. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MaxCyte recorded a loss per share of 0.39. The entity had not issued any dividends in recent years.
To determine if MaxCyte is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding MaxCyte's research are outlined below:
| MaxCyte generated a negative expected return over the last 90 days | |
| MaxCyte has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 38.63 M. Net Loss for the year was (41.05 M) with profit before overhead, payroll, taxes, and interest of 31.53 M. | |
| MaxCyte currently holds about 240.89 M in cash with (27.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37. | |
| Roughly 74.0% of the company shares are owned by institutional investors |
MaxCyte uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in MaxCyte. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to MaxCyte's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
MaxCyte's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 345.65 M.MaxCyte's profitablity analysis
The company has Profit Margin (PM) of (1.06) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.48) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.48.Determining MaxCyte's profitability involves analyzing its financial statements and using various financial metrics to determine if MaxCyte is a good buy. For example, gross profit margin measures MaxCyte's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of MaxCyte's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in MaxCyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MaxCyte. Check MaxCyte's Beneish M Score to see the likelihood of MaxCyte's management manipulating its earnings.
Basic technical analysis of MaxCyte Stock
As of the 19th of March, MaxCyte secures the Risk Adjusted Performance of (0.09), standard deviation of 3.46, and Mean Deviation of 2.66. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MaxCyte, as well as the relationship between them.MaxCyte's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MaxCyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on MaxCyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MaxCyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MaxCyte's Outstanding Corporate Bonds
MaxCyte issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MaxCyte uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MaxCyte bonds can be classified according to their maturity, which is the date when MaxCyte has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MAY DEPT STORES Corp BondUS577778BH56 | View | |
| MAY DEPT STORES Corp BondUS577778BQ55 | View | |
| MAY DEPT STORES Corp BondUS577778CE17 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand MaxCyte's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing MaxCyte's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.35) | |||
| Mean Deviation | 2.66 | |||
| Coefficient Of Variation | (903.13) | |||
| Standard Deviation | 3.46 | |||
| Variance | 11.95 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.01) | |||
| Treynor Ratio | (0.36) | |||
| Maximum Drawdown | 19.95 | |||
| Value At Risk | (5.50) | |||
| Potential Upside | 5.78 | |||
| Skewness | 0.7529 | |||
| Kurtosis | 1.6 |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.35) | |||
| Mean Deviation | 2.66 | |||
| Coefficient Of Variation | (903.13) | |||
| Standard Deviation | 3.46 | |||
| Variance | 11.95 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.01) | |||
| Treynor Ratio | (0.36) | |||
| Maximum Drawdown | 19.95 | |||
| Value At Risk | (5.50) | |||
| Potential Upside | 5.78 | |||
| Skewness | 0.7529 | |||
| Kurtosis | 1.6 |
Consider MaxCyte's intraday indicators
MaxCyte intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MaxCyte stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
MaxCyte time-series forecasting models is one of many MaxCyte's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary MaxCyte's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
MaxCyte Stock media impact
Far too much social signal, news, headlines, and media speculation about MaxCyte that are available to investors today. That information is available publicly through MaxCyte media outlets and privately through word of mouth or via MaxCyte internal channels. However, regardless of the origin, that massive amount of MaxCyte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of MaxCyte news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MaxCyte relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MaxCyte's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MaxCyte alpha.
MaxCyte Corporate Management
| James Brady | Senior Support | Profile | |
| Stark Thompson | Consultant | Profile | |
| Jill Mayer | Senior Resources | Profile | |
| Cenk Sumen | Chief Officer | Profile | |
| Douglas Doerfler | President, Founder | Profile | |
| Jay Gelfman | Senior Operations | Profile |
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.